Table 1.
Baseline characteristics and pathologic response rates for the entire cohort (105 patients) and by institution
| Patient characteristics | NYU (N = 36) | USC (N = 33) | Vanderbilt (N = 36) | Total (N = 105) | All group P-value |
|---|---|---|---|---|---|
| Race | |||||
| Caucasian | 13 (36%) | 5 (15%) | 30 (83%) | 48 (46%) | <0.001a,^ |
| Non-Caucasian | 23 (64%) | 28 (85%) | 6 (17%) | 57 (54%) | |
| Hispanic | 7 (19%) | 21 (64%) | 0 | 28 (27%) | |
| African American | 7 (19%) | 1 (3%) | 5 (14%) | 13 (12%) | |
| Asian | 9 (25%) | 6 (18%) | 1 (3%) | 16 (15%) | |
| Age | Mean = 50.0 | Mean = 48.5 | Mean = 47.4 | Mean = 48.6 | 0.64c |
| SD = 11.06 | SD = 12.3 S | D = 11.4 | SD = 11.5 | ||
| Age ≤ 50 | 20 (56%) | 21 (64%) | 20 (56%) | 61 (58%) | 0.74a |
| Age > 50 | 16 (44%) | 12 (36%) | 16 (44%) | 44 (42%) | |
| AJCC Stage | |||||
| II | 19 (53%) | 10 (31%) | 22 (61%) | 51 (49%) | 0.04a |
| III | 17 (47%) | 22 (69%) | 14 (39%) | 53 (51%) | |
| Missing | 1 | 1 | |||
| Tumor Grade | |||||
| I | 1 (3%) | 0 | 4 (11%) | 5 (7%) | 0.44b |
| II | 14 (41%) | 0 | 14 (39%) | 28 (38%) | |
| III | 19 (56%) | 3 (100%) | 18 (50%) | 40 (55%) | |
| Missingd | 2 | 30 | 32 | ||
| ER | |||||
| Negative | 12 (33%) | 19 (58%) | 19 (53%) | 50 (48%) | 0.10a |
| Positive | 24 (67%) | 14 (42%) | 17 (47%) | 55 (52%) | |
| PR | |||||
| Negative | 22 (61%) | 20 (61%) | 22 (61%) | 64 (61%) | 1.00a |
| Positive | 14 (39%) | 13 (39%) | 14 (39%) | 41 (39%) | |
| HR status | |||||
| Negative | 12 (33%) | 17 (52%) | 19 (53%) | 48 (46%) | 0.18a,^^ |
| Positive | 24 (67%) | 16 (48%) | 17 (47%) | 57 (54%) | |
| ER+PR− | 10 (28%) | 3 (9%) | 3 (8%) | 16 (15%) | |
| ER+PR+ | 14 (39%) | 11 (33%) | 14 (39%) | 39 (37%) | |
| ER−PR+ | 0 | 2 (6%) | 0 | 2 (2%) | |
| Her2 status | |||||
| Negative | 26 (72%) | 11 (79%) | 21 (60%) | 58 (68%) | 0.36a |
| Positive | 10 (28%) | 3 (21%) | 14 (40%) | 27 (32%) | |
| Missing | 19 | 1 | 20 | ||
| Pathologic response | |||||
| pCR/pPR | 11 (31%) | 10 (30%) | 15 (42%) | 36 (34%) | 0.52a |
| pCR | 8 (22%) | 5 (15%) | 11 (31%) | 24 (23%) | |
| pPR | 3 (8%) | 5 (15%) | 4 (11%) | 12 (11%) | |
| pNR | 25 (69%) | 23 (70%) | 21 (58%) | 69 (66%) |
NYU New York University, USC University of Southern California, N number, SD standard deviation, AJCC American Joint Commission on Cancer, ER estrogen receptor, PR progesterone receptor, Her2 human epidermal growth factor receptor, pCR pathologic complete response, pPR pathologic partial response, pNR no pathologic response
^
P-values based on Caucasian vs. non Caucasian
^^
P-value base on positive versus negative
a
Chi-square test
b
Fisher exact test
c
F-Statistic
d
Only nuclear grade was reported